Bevacizumab

In this article, we will discuss about Bevacizumab (Dosage). So, let’s get started.

Indications

Metastatic Colorectal Cancer (mCRC)

Bevacizumab (Avastin®), in combination with intravenous 5-fluorouracil-based chemotherapy, is indicated for the first-or second-line treatment of patients with metastatic colorectal cancer.

Bevacizumab (Avastin®), in combination with fluoropyrimidine-innotecan-or fluoropyrimidine-oxaliplatin-based
chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Bevacizumab (Avastin®)-containing regimen.

Limitation of Use: Bevacizumab (Avastin®) is not indicated for adjuvant treatment of colon cancer.

First-Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Bevacizumab (Avastin®), in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell
lung cancer

Recurrent Glioblastoma (GBM)

Bevacizumab (Avastin®) is indicated for the treatment of recurrent glioblastoma in adults.

Metastatic Renal Cell Carcinoma (mRCC)

Bevacizumab (Avastin®), in combination with interferon alfa, is indicated for the treatment of metastatic renal cell
carcinoma

Persistent, Recurrent, or Metastatic Cervical Cancer

Bevacizumab (Avastin®), in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.

Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Bevacizumab (Avastin®), in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated
for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.

Bevacizumab (Avastin®), in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-
sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Dosage

Important Administration Information

Do not administer Bevacizumab (Avastin®) until at least 28 days following surgery and the wound is fully healed.

Metastatic Colorectal Cancer (mCRC)

The recommended dose when Bevacizumab (Avastin®) is administered in combination with intravenous
5-fluorouracil-based chemotherapy is:
• 5 mg/kg every 2 weeks intravenously in combination with bolus-IFL.
• 10 mg/kg every 2 weeks intravenously in combination with FOLFOX4.
• 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line Bevacizumab (Avastin®)-containing regimen.

First-Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

The recommended dose is 15 mg/kg intravenously every 3 weeks in combination with carboplatin
and paclitaxel.

Recurrent Glioblastoma (GBM)

The recommended dose is 10 mg/kg intravenously every 2 weeks.

Metastatic Renal Cell Carcinoma (mRCC)

The recommended dose is 10 mg/kg intravenously every 2 weeks in combination with interferon alfa.

Persistent, Recurrent, or Metastatic Cervical Cancer

The recommended dose of Avastin is 15 mg/kg intravenously every 3 weeks in combination with paclitaxel and cisplatin or in combination with paclitaxel and topotecan.

Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Platinum Resistant

The recommended dose is 10 mg/kg intravenously every 2 weeks in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan (every week).

The recommended dose is 15 mg/kg intravenously every 3 weeks in combination with topotecan (every 3 weeks)

Platinum Sensitive

The recommended dose is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin and paclitaxel for 6 to 8 cycles, followed by Bevacizumab (Avastin®) 15 mg/kg every 3 weeks as a single agent until disease progression.

The recommended dose is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin and gemcitabine for 6 to 10 cycles, followed by Bevacizumab (Avastin®) 15 mg/kg every 3 weeks as a single agent until disease progression.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.